Changeflow GovPing Healthcare & Life Sciences Gamma-hydroxybutyrate Formulations with Improve...
Routine Notice Added Final

Gamma-hydroxybutyrate Formulations with Improved Pharmacokinetics

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a new patent application, US20260083696A1, detailing modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties. The application was filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The United States Patent and Trademark Office (USPTO) has published patent application US20260083696A1, titled 'Gamma-hydroxybutyrate formulations with improved pharmacokinetics.' This application, filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson, describes novel modified release formulations of gamma-hydroxybutyrate designed to enhance dissolution and pharmacokinetic properties.

This publication represents a new patent filing and does not impose immediate compliance obligations. However, it is relevant for pharmaceutical companies and drug manufacturers involved in the development or research of gamma-hydroxybutyrate or similar formulations. Compliance officers should note this filing as it pertains to intellectual property within the pharmaceutical sector, potentially impacting future product development and market exclusivity.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

Application US20260083696A1 Kind: A1 Mar 26, 2026

Inventors

Jordan Dubow, Claire Megret, Hervé Guillard, Jean-François Dubuisson

Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

CPC Classifications

A61K 31/22 A61K 9/14 A61K 9/1676 A61K 9/5015 A61K 9/5026 A61K 9/5042 A61K 9/5078 A61K 9/5084 A61K 31/19

Filing Date

2025-10-01

Application No.

19347400

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
October 1st, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083696A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Intellectual Property Filing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!